Daily Technical Summary Reports on Biotech Stocks -- Actinium Pharma, BioPharmX, Matinas BioPharma, and 22nd Century
NEW YORK, August 30, 2017 /PRNewswire/ --
If you want a Stock Review on ATNM, BPMX, MTNB, or XXII then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com revisits the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. Under assessment this morning are: Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM), BioPharmX Corp. (NYSEMKT: BPMX), Matinas BioPharma Holdings Inc. (NYSEMKT: MTNB), and 22nd Century Group Inc. (NYSEMKT: XXII). Register now and get full and free access to these DailyStockTracker.com research reports at:
http://dailystocktracker.com/register/
Actinium Pharma
On Tuesday, shares in New York-based Actinium Pharmaceuticals Inc. recorded a trading volume of 190,590 shares. The stock ended at $0.59, jumping 5.37% from the last trading session. The Company's shares are trading below their 50-day moving average by 32.99%. Furthermore, shares of Actinium Pharma, which develops targeted payload immunotherapeutics for the treatment of advanced cancers, have a Relative Strength Index (RSI) of 32.76.
On August 02nd, 2017, Actinium Pharma announced the closing of the Company's previously announced underwritten public offering of 21,500,000 shares of its common stock and warrants to purchase an aggregate of 18,275,000 shares of its common stock at an offering price to the public of $0.75 per share and related warrant. The warrants have an exercise price of $1.05 per share and have a term of exercise of five years. Access our complete research report on ATNM for free at:
http://dailystocktracker.com/registration/?symbol=ATNM
BioPharmX
Menlo Park, California headquartered BioPharmX Corp.'s stock finished yesterday's session 2.54% higher at $0.29 with a total trading volume of 328,731 shares. The Company's shares are trading below their 50-day moving average by 24.58%. Shares of the Company, which develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets, have an RSI of 38.81. The complimentary research report on BPMX can be downloaded at:
http://dailystocktracker.com/registration/?symbol=BPMX
Matinas BioPharma Holdings
At the close of trading on Tuesday, shares in Bedminster, New Jersey-based Matinas BioPharma Holdings Inc. saw a slight drop of 0.74%, ending the day at $1.34. The stock recorded a trading volume of 125,036 shares. The Company's shares have advanced 19.64% in the last one month. The stock is trading 12.83% below its 50-day moving average. Moreover, shares of Matinas BioPharma, which focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections, have an RSI of 48.07.
On August 08th, 2017, Matinas BioPharma announced its financial results for the three months ended June 30th, 2017. For Q2 2017, net loss was approximately $3.9 million; R&D expenses were $2.3 million, and G&A expenses were $1.7 million. The Company ended the quarter with cash and cash equivalents of approximately $11.2 million. Register for free on DailyStockTracker.com and get access to the latest report on MTNB at:
http://dailystocktracker.com/registration/?symbol=MTNB
22nd Century Group
Clarence, New York headquartered 22nd Century Group Inc.'s shares ended the day 2.23% lower at $2.19 with a total trading volume of 1.24 million shares. The stock has surged 25.14% in the last month, 59.85% over the previous three months, and 100.92% on an YTD basis. The Company's shares are trading 16.76% above their 50-day moving average and 64.40% above their 200-day moving average. Additionally, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 56.14.
On August 23rd, 2017, 22nd Century announced that a growing number of independent scientists specializing in tobacco harm reduction are publicly proclaiming that the FDA's recently announced plan to reduce nicotine to non-addictive levels in cigarettes will drastically improve public health. Noted experts have proclaimed that Very Low Nicotine cigarettes will "end the combustible tobacco epidemic" and "could save more lives than any other act of a governmental agency in all of human history". Download your free research report on XXII at:
http://dailystocktracker.com/registration/?symbol=XXII
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
Share this article